Taiwan Continuous Glucose Monitoring Market Size, Share, Trends and Forecasts 2031

Key Findings

• The Taiwan Continuous Glucose Monitoring Market is witnessing rapid adoption as patients and healthcare providers seek real-time, accurate glucose monitoring solutions for better diabetes management.
• CGM devices in Taiwan are increasingly replacing traditional blood glucose meters due to their ability to provide continuous insights, predictive alerts, and integration with digital health platforms.
• Rising prevalence of diabetes and prediabetes in Taiwan is accelerating the demand for advanced glucose monitoring technologies.
• Integration of CGM with insulin pumps and artificial pancreas systems is enhancing therapeutic outcomes for patients with Type 1 and Type 2 diabetes.
• Remote patient monitoring and telehealth expansion in Taiwan are boosting CGM adoption as part of digital healthcare ecosystems.
• Favorable government policies, reimbursement initiatives, and awareness campaigns are supporting CGM penetration in Taiwan.
• Wearable sensor innovations, extended sensor life, and minimally invasive designs are driving consumer acceptance in Taiwan.
• Strategic partnerships between device manufacturers and healthcare providers are broadening access to CGM technologies in Taiwan.

Taiwan Continuous Glucose Monitoring Market Size and Forecast

The Taiwan Continuous Glucose Monitoring Market is projected to grow from USD 2.84 billion in 2025 to USD 7.92 billion by 2031, at a CAGR of 18.5% during the forecast period. This growth is primarily fueled by the rising incidence of diabetes, technological advancements in wearable sensors, and the integration of CGM into broader healthcare management systems. With expanding healthcare infrastructure and growing patient awareness in Taiwan, the CGM market is set to transform diabetes care across both urban and rural populations.

Introduction

Continuous glucose monitoring is a revolutionary technology that allows patients to track glucose levels in real time using minimally invasive sensors. Unlike conventional fingerstick methods, CGM provides a complete profile of glucose fluctuations, enabling better disease management and reducing risks of hypo- and hyperglycemia. In Taiwan, the rising diabetes burden is putting pressure on healthcare systems to adopt advanced monitoring solutions. CGM adoption is also being driven by growing patient awareness, government initiatives, and the push toward personalized healthcare.

Future Outlook

By 2031, CGM in Taiwan will become a standard component of diabetes management, with widespread use across both Type 1 and Type 2 diabetes patients. Advancements in non-invasive sensor technology and integration with AI-driven platforms will provide patients with predictive insights and personalized recommendations. Digital health ecosystems in Taiwan will incorporate CGM data for improved care coordination, especially in remote and underserved regions. Reimbursement frameworks will further boost access, and patient-centric innovations such as long-lasting sensors and smartphone integration will expand adoption.

Taiwan Continuous Glucose Monitoring Market Trends

• Integration of CGM with Digital Health Platforms
  In Taiwan, CGM systems are increasingly integrated with smartphone apps, cloud platforms, and digital health ecosystems. This connectivity allows real-time glucose data sharing with patients, caregivers, and healthcare providers, improving diabetes management outcomes. Digital integration also supports remote monitoring, a critical factor in regions with limited access to endocrinologists. Patients benefit from predictive alerts and actionable insights generated through AI-powered platforms. This trend reflects the broader shift toward data-driven healthcare solutions.
• Shift Toward Minimally Invasive and Non-Invasive Sensors
  Advances in material science and biomedical engineering are driving the development of less invasive and fully non-invasive CGM devices in Taiwan. Traditional subcutaneous sensors are being enhanced with longer wear times and reduced calibration needs. Research into non-invasive methods, such as optical and transdermal monitoring, is progressing rapidly. These innovations are improving patient comfort and compliance, which are critical for long-term CGM use. The trend underscores growing consumer demand for convenience and ease of use in medical devices.
• Expansion of CGM Use Beyond Type 1 Diabetes
  While CGM has traditionally been used by Type 1 diabetes patients, adoption among Type 2 diabetes and prediabetic populations in Taiwan is increasing. Physicians are recommending CGM for patients on insulin therapy as well as those managing diabetes through lifestyle changes. This broader application is expanding the addressable market for CGM devices significantly. Growing clinical evidence supporting CGM use in Type 2 diabetes is accelerating its integration into standard care protocols. The trend highlights the role of CGM in proactive and preventive healthcare.
• Growth of Remote Monitoring and Telehealth
  The COVID-19 pandemic accelerated the adoption of telehealth in Taiwan, and CGM has become a vital tool in this ecosystem. CGM data can be transmitted remotely, enabling virtual consultations and real-time treatment adjustments. This capability is particularly valuable in rural and underserved areas where access to specialized care is limited. Remote monitoring also reduces the need for frequent in-person visits, lowering the burden on healthcare systems. The trend is expected to grow as digital healthcare infrastructure strengthens in Taiwan.
• Increasing Collaborations Between Manufacturers and Providers
  CGM adoption in Taiwan is being fueled by partnerships between device manufacturers, healthcare providers, and payers. Such collaborations focus on expanding patient access through reimbursement programs, clinical education, and integrated care models. Manufacturers are working with hospitals and clinics to embed CGM into diabetes management pathways. These partnerships are also addressing affordability challenges through subscription models and financing options. The trend is strengthening the ecosystem required for sustainable CGM adoption.

Market Growth Drivers

• Rising Diabetes Prevalence in Taiwan
  The growing incidence of diabetes in Taiwan, driven by lifestyle factors, aging populations, and urbanization, is significantly increasing demand for CGM solutions. Diabetes management requires continuous monitoring to prevent complications such as cardiovascular disease and kidney failure. CGM provides a reliable tool for maintaining optimal glucose control. The rising patient population creates a sustained demand for advanced monitoring technologies. This demographic trend is one of the strongest drivers of market growth in the region.
• Technological Advancements in CGM Devices
  Innovations in CGM device design are making systems more user-friendly, accurate, and long-lasting in Taiwan. Extended sensor wear times, reduced calibration needs, and wireless connectivity are enhancing adoption. These technological improvements reduce patient burden while improving treatment adherence. Enhanced sensor accuracy allows physicians to rely more confidently on CGM data for treatment adjustments. Such advancements are a major catalyst for market expansion across healthcare systems in Taiwan.
• Favorable Government and Reimbursement Policies
  Policymakers in Taiwan are increasingly recognizing the role of CGM in reducing long-term healthcare costs associated with diabetes complications. Governments are introducing subsidies and reimbursement schemes to improve affordability for patients. These initiatives encourage wider adoption among middle- and lower-income populations. Insurance coverage of CGM is further expanding patient access. Supportive policy frameworks are creating a strong foundation for sustained market growth in Taiwan.
• Shift Toward Personalized and Preventive Healthcare
  CGM is becoming central to personalized diabetes care in Taiwan, as it provides insights into individual glucose responses to diet, exercise, and medication. Physicians are leveraging CGM data to tailor treatment plans and prevent complications. This focus on prevention aligns with global healthcare trends that emphasize reducing disease burden through proactive management. As more patients adopt CGM for preventive purposes, the market is expanding beyond traditional diabetes management. The shift is strengthening CGM’s role in holistic health management.
• Expansion of Telehealth and Remote Patient Monitoring
  Growing investments in telehealth infrastructure in Taiwan are boosting the adoption of CGM as part of virtual care models. CGM enables continuous monitoring without the need for frequent hospital visits, reducing patient inconvenience. Remote monitoring platforms integrate CGM data for physician review during virtual consultations. This driver is especially important in rural and underserved areas with limited access to specialized care. The integration of CGM into telehealth systems ensures its long-term relevance in modern healthcare.

Challenges in the Market

• High Cost of CGM Devices
  Despite technological advancements, CGM devices remain costly in Taiwan, limiting adoption among lower-income populations. High upfront costs for sensors and transmitters, combined with recurring expenses for replacements, create affordability barriers. Even with reimbursement support, many patients find CGM financially challenging. The cost factor restricts widespread adoption, particularly in emerging markets. Addressing pricing and affordability will be essential for the long-term sustainability of the market.
• Limited Awareness and Education
  In Taiwan, patient and physician awareness about the benefits of CGM is still limited outside major urban centers. Many patients continue relying on traditional fingerstick testing due to lack of knowledge or misconceptions about CGM. Similarly, some physicians hesitate to recommend CGM due to unfamiliarity with interpreting continuous data. Awareness campaigns and training programs are needed to expand adoption. Without adequate education, CGM penetration will remain below its full potential.
• Data Privacy and Security Concerns
  As CGM devices become integrated with digital platforms, concerns about patient data privacy and cybersecurity are rising in Taiwan. Continuous data transmission exposes patients to risks of unauthorized access or misuse of sensitive health information. Regulatory frameworks for digital health data remain underdeveloped in many regions. Addressing security concerns is critical for building trust among patients and providers. Without robust safeguards, digital integration could face resistance.
• Shortage of Trained Healthcare Professionals
  Effective use of CGM requires trained healthcare professionals who can interpret data and adjust treatment plans accordingly. In Taiwan, shortages of endocrinologists and diabetes educators are limiting CGM adoption. Patients in rural areas face greater challenges in accessing trained professionals. This shortage undermines the potential benefits of CGM even where devices are available. Expanding training programs and integrating CGM into general practice are essential to overcome this challenge.
• Device Accuracy and Calibration Limitations
  Although CGM devices have improved significantly, accuracy and calibration issues remain concerns in Taiwan. Sensor lag, calibration requirements, and performance variations during extreme glucose fluctuations can affect reliability. These limitations sometimes discourage adoption among patients and physicians. Ongoing technological innovation is required to address accuracy concerns fully. Until then, reliability issues will remain a barrier to widespread CGM adoption.

Taiwan Continuous Glucose Monitoring Market Segmentation

By Component

• Sensors
• Transmitters
• Receivers/Monitors

By End-User

• Hospitals & Clinics
• Homecare Settings
• Diagnostic Centers

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Leading Key Players

• Dexcom, Inc.
• Abbott Laboratories
• Medtronic plc
• Senseonics Holdings, Inc.
• Ascensia Diabetes Care
• Roche Diabetes Care
• Ypsomed AG
• AgaMatrix, Inc.
• LifeScan, Inc.
• GlucoMe Ltd.

Recent Developments

• Dexcom expanded its presence in Taiwan with the launch of a next-generation CGM sensor offering extended wear times.
• Abbott introduced cost-effective CGM solutions in Taiwan targeting broader patient access.
• Medtronic partnered with hospitals in Taiwan to integrate CGM data into digital diabetes management programs.
• Senseonics rolled out implantable CGM systems in Taiwan, offering long-term wear options for patients.
• Ascensia Diabetes Care announced collaborations in Taiwan to improve awareness and adoption of CGM technologies.

This Market Report Will Answer the Following Questions

1. What is the projected market size and CAGR of the Taiwan Continuous Glucose Monitoring Market by 2031?
2. Which factors are driving CGM adoption in Taiwan?
3. What are the major technological advancements shaping CGM innovation?
4. What barriers are limiting CGM penetration in Taiwan?
5. Who are the leading companies in the Taiwan Continuous Glucose Monitoring Market?

Other Related Regional Reports Of Continuous Glucose Monitoring Market